|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2020-02-27
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N02CD07
|
|
gptkbp:brand
|
gptkb:Nurtec_ODT
gptkb:Vydura_(EU)
|
|
gptkbp:chemicalClass
|
gptkb:small_molecule
|
|
gptkbp:contraindication
|
hypersensitivity to rimegepant
|
|
gptkbp:drugClass
|
CGRP receptor antagonist
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:form
|
orally disintegrating tablet
75 mg
|
|
gptkbp:genericName
|
rimegepant
|
|
gptkbp:halfLife
|
11 hours
|
|
gptkbp:indication
|
acute treatment of migraine
preventive treatment of episodic migraine
|
|
gptkbp:legalStatus
|
Rx-only (US)
|
|
gptkbp:license
|
gptkb:Pfizer_(outside_US)
|
|
gptkbp:manufacturer
|
gptkb:Biohaven_Pharmaceuticals
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
CGRP receptor antagonist
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
rash
hypersensitivity
dyspnea
|
|
gptkbp:usedFor
|
migraine treatment
|
|
gptkbp:bfsParent
|
gptkb:Rick_Ware_Racing
gptkb:Biohaven_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nurtec ODT
|